Last Price$33.90.6%
Market Cap$15.2B
Last Earnings date
Sep'24
Q3 2024
$0.46
51.7% miss
$594.0M
9.3% miss
Next quarter EPS Estimate
$1.12
(2.6%)YoY
RPRX Earnings and Expectations
Revenue
Crunching data... Almost there!
RPRX EPS (Earnings Per Share)
Crunching data... Almost there!
RPRX Historical Revenue & EPS and Expectations
1Y
3Y
5Y
10Y
Revenue
EPS
RPRX Earnings History
| Mar'19 | Jun'19 | Sep'19 | Dec'19 | Mar'20 | Jun'20 | Sep'20 | Dec'20 | Mar'21 | Jun'21 | Sep'21 | Dec'21 | Mar'22 | Jun'22 | Sep'22 | Dec'22 | Mar'23 | Jun'23 | Sep'23 | Dec'23 | Mar'24 | Jun'24 | Sep'24 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue actual | $434.9M | $457.6M | $464.3M | $457.5M | $500.9M | $510.9M | $539.0M | $571.0M | $573.0M | $555.0M | $585.8M | $575.7M | $562.0M | $536.0M | $573.5M | $565.7M | $684.0M | $538.2M | $536.3M | $596.0M | $568.0M | $537.3M | $564.7M | $594.0M |
| Revenue estimate | N/A | N/A | N/A | N/A | N/A | $468.9M | $451.7M | $484.0M | $511.7M | $484.3M | $563.1M | $552.1M | $597.0M | $528.4M | $586.3M | $1,064.1M | $902.0M | $543.7M | $631.7M | $685.5M | $665.6M | $627.4M | $696.9M | $655.2M |
| Revenue surprise | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 9.0% | 19.3% | 18.0% | 12.0% | 14.6% | 4.0% | 4.3% | 5.9% | 1.4% | 2.2% | 46.8% | 24.2% | 1.0% | 15.1% | 13.1% | 14.7% | 14.4% | 19.0% | 9.3% |
| EPS actual | $1.04 | $0.43 | $1.15 | $4.01 | $0.20 | $0.09 | $0.79 | $0.44 | $0.18 | $1.08 | $0.24 | $0.02 | ($0.07) | $0.50 | $0.36 | ($1.38) | $0.76 | $0.51 | $0.16 | $1.11 | $0.01 | $0.23 | $1.61 | $0.46 |
| EPS estimate | N/A | N/A | N/A | N/A | N/A | $0.61 | $0.59 | $0.71 | $0.66 | $0.70 | $0.70 | $0.78 | $0.73 | $0.78 | $0.71 | $1.47 | $1.27 | $0.83 | $0.77 | $1.01 | $0.99 | $0.97 | $0.93 | $0.95 |
| EPS surprise | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 85.2% | 33.7% | 37.6% | 72.6% | 53.6% | 65.7% | 98.0% | 109.0% | 36.0% | 49.2% | 193.7% | 40.3% | 38.6% | 79.2% | 9.9% | 98.9% | 76.2% | 73.6% | 51.7% |
Overview of financial statements
Income statement
Balance sheet
Cash Flow statement
$594.0M (0.3%) YoY
Pre-tax income
$334.0M (53.5%) YoY
56.2% margin
Competing with RPRX Earnings
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Revenue | EPS | Last quarter Revenue growth | Last quarter EPS growth | Last quarter Revenue surprise | Last quarter EPS surprise | Next quarter Revenue growth | Next quarter EPS growth | Last 10 Earnings (how many miss vs beat) | 1Y Fwd Revenue growth | 1Y Fwd EPS growth |
$15.2B | $2,263.9M | $2.31 | (0.3%) | (58.6%) | Miss by 9.3% | Miss by 51.7% | 34.5% | 138.0% | Beats: 5 Misses: 5 | 35.2% | 132.7% | |
$402.0B | DKK 290.4B | DKK 22.67 | 30.1% | 28.9% | Beat by 7.6% | Beat by 5.2% | (7.2%) | 1.8% | Beats: 5 Misses: 5 | 19.9% | 23.5% | |
$125.5B | $11.0B | ($2.06) | 15.7% | (5.6%) | Beat by 4.5% | Miss by 11.1% | (3.9%) | 23.5% | Beats: 8 Misses: 2 | 6.8% | (988.1%) | |
$74.0B | $14.2B | $40.88 | 10.3% | (21.6%) | Beat by 0.8% | Miss by 24.2% | (7.6%) | 23.7% | Beats: 7 Misses: 3 | 3.4% | 9.5% | |
$38.1B | $2,258.9M | ($1.77) | 73.8% | N/A | Beat by 40.1% | Miss by 281.3% | 23.0% | (6.7%) | Beats: 8 Misses: 2 | 76.7% | (141.9%) | |
$31.3B | $2,248.2M | ($2.17) | 34.9% | (40.9%) | Beat by 1.6% | Beat by 27.8% | (7.3%) | 14.2% | Beats: 7 Misses: 3 | 16.9% | (55.3%) | |
$27.1B | €3,040.1M | (€1.96) | 39.0% | 20.3% | Beat by 761.0% | Miss by 141.1% | (10.3%) | (51.6%) | Beats: 5 Misses: 5 | (28.2%) | (182.9%) | |
$14.8B | $4,241.2M | $0.24 | 16.3% | 7.8% | Beat by 3.4% | Miss by 35.6% | (14.7%) | 12.1% | Beats: 3 Misses: 7 | 9.3% | 3,612.9% | |
$14.6B | $0.0 | ($0.22) | (100.0%) | (100.0%) | undefinedN/A | undefinedN/A | 0.0% | 0.0% | Beats: Misses: | N/A | 6.8% | |
$14.0B | $2,877.4M | $26.45 | 19.7% | 45.9% | Miss by 0.5% | Beat by 2.4% | 3.0% | 6.7% | Beats: 5 Misses: 5 | 10.7% | 9.9% |
FAQ
1. When was Royalty Pharma plc's last earnings date?
Royalty Pharma plc's last earnings date was Sep'24 (Q3 2024).
2. What is Royalty Pharma plc's EPS, and was there a surprise?
Royalty Pharma plc's EPS was $0.46, with a 51.7% miss.
3. What is Royalty Pharma plc's revenue, and was there a surprise?
Royalty Pharma plc's revenue was $594.0M, with a 9.3% miss.
4. What is Royalty Pharma plc's next quarter EPS estimate?
Royalty Pharma plc's next quarter EPS estimate is $1.12, with an expected (2.6%) YoY growth.